Citation

BibTex format

@article{Mayer-Hamblett:2025:10.1016/S2213-2600(25)00206-1,
author = {Mayer-Hamblett, N and Kerper, NR and Clancy, JP and Davies, JC and Taylor-Cousar, JL and Donaldson, SH and Bell, SC and Jain, R and Simmonds, NJ and Mall, MA and Goss, CH and Rayment, JH and Setiawan, L and Pilewski, JM},
doi = {10.1016/S2213-2600(25)00206-1},
journal = {LANCET RESPIRATORY MEDICINE},
title = {Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials},
url = {http://dx.doi.org/10.1016/S2213-2600(25)00206-1},
volume = {13},
year = {2025}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Mayer-Hamblett,N
AU  - Kerper,NR
AU  - Clancy,JP
AU  - Davies,JC
AU  - Taylor-Cousar,JL
AU  - Donaldson,SH
AU  - Bell,SC
AU  - Jain,R
AU  - Simmonds,NJ
AU  - Mall,MA
AU  - Goss,CH
AU  - Rayment,JH
AU  - Setiawan,L
AU  - Pilewski,JM
DO  - 10.1016/S2213-2600(25)00206-1
PY  - 2025///
SN  - 2213-2600
TI  - Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials
T2  - LANCET RESPIRATORY MEDICINE
UR  - http://dx.doi.org/10.1016/S2213-2600(25)00206-1
VL  - 13
ER  -
Download
Read the HIC-Vac blog
  • News
  • Interview

An interview with Professor Openshaw

Professor Peter Openshaw is interviewed by the Infectious Diseases Hub on influenza and immunopathogenesis